Does Pfizer Inc. (PFE)’s Unwinding of Its Stake in Zoetis Inc (ZTS) Offer Value for Either Company’s Shareholders?

Page 1 of 2

Pfizer Inc. (NYSE:PFEsurprised the investment community with the recent announcement that it would attempt to offload the remainder of its stake in veterinary pharmaceutical firm Zoetis Inc (NYSE:ZTS). At minimum, the transaction would be designed to reduce Pfizer’s take in Zoetis to non-majority, non-controlling levels. However, the ultimate goal appears to be the complete liquidation of Pfizer’s interest in its former subsidiary. Although many industry observers expected that this would eventually occur, many have been surprised by the speed and efficacy with which Pfizer appears to be committed to divorcing itself from Zoetis.

Pfizer Inc. (NYSE:PFE)

This transaction could offer a few key advantages for rank-and-file Pfizer investors. On the other hand, it might temporarily impact the earning power of newly minted Zoetis Inc (NYSE:ZTS) shareholders. However, both of these companies are strong and seem well-prepared to handle temporary volatility. Investors who wish to profit from this special situation should start by comparing Pfizer Inc. (NYSE:PFE), Zoetis and other major drug-makers.

Pfizer, Zoetis and the Competition

Pfizer competes with several major pharmaceutical companies as well as a number of smaller, more narrowly focused outfits. Although it does not enjoy much operational overlap, Zoetis Inc (NYSE:ZTS) also competes with major drug-makers by virtue of its size. One of both firms’ closest competitors is Merck & Co., Inc. (NYSE:MRK) .

Pfizer Inc. (NYSE:PFE) and Merck are far larger than Zoetis. At last count, Pfizer’s market capitalization came in at just over $205 billion. Merck enjoyed a market valuation of around $142 billion. Meanwhile, Zoetis reported a comparatively puny valuation of about $16.7 billion. Despite its enormous size, Pfizer is currently the most profitable of these three firms: At 27%, its profit margin is roughly double that of Merck and (NYSE:MRK) exceeds that of Zoetis by a factor of three. Moreover, Pfizer reported an impressive quarterly earnings growth figure of over 50%. With an earnings increase of 26%, Zoetis also appears to be enjoying some profit momentum. By comparison, Merck recently saw its quarterly earnings shrink by a little over 8 percent.

With just slightly more debt than cash and strongly positive cash flow figures, Pfizer and Merck have similar-looking balance sheets. By comparison, Zoetis Inc (NYSE:ZTS)’s financials look slightly weaker: The company has about $3.7 billion in debt to just $468 million in cash. Fortunately, it has an operating cash flow of around $740 million.

How the Deal Is Structured

According to the terms of the deal, all Pfizer Inc. (NYSE:PFE) shareholders are currently eligible to participate in this secondary offering. The offering will be structured as a one-way share swap. As soon as the program begins, individual Pfizer shareholders will be permitted to exchange their holdings for proportional numbers of Zoetis shares. To increase interest in the offering, Pfizer has indicated that shareholders who participate in the deal will earn a premium of between 7 and 8 percent. Although the exact premium will be based on pre-closing trading averages and will not be announced until June 19, it is currently expected to be near 7.5 percent. In other words, Pfizer shareholders who participate in the swap will receive “extra” Zoetis Inc (NYSE:ZTS) shares valued at 7.5 percent of their previous Pfizer holdings.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!